Device-supported vs routine titration of insulin glargine 300 U/ml (Gla-300) in type 2 diabetes: efficacy and safety

被引：0
|
作者：
Flacke, F. [1 ]
Edelman, S. [2 ]
Bain, S. [3 ]
Hasslacher, C. [4 ]
Charpentier, G. [5 ]
Vespasiani, G. [6 ]
Goyeau, H. [7 ]
Woloschak, M. [8 ]
Davies, M. [9 ]
机构：
[1] Sanofi, Frankfurt, Germany
[2] Univ Calif San Diego, La Jolla, CA 92093 USA
[3] Swansea Univ, Inst Life Sci, Coll Med, Sch Med, Swansea, W Glam, Wales
[4] Diabet Inst Heidelberg, Heidelberg, Germany
[5] Sud Francilien Hosp, Dept Med, Corbeil Essonnes, France
[6] Ctr Outcomes Res & Clin Epidemiol, Pescara, Italy
[7] Sanofi, Chilly Mazarin, France
[8] Sanofi, New York, NY USA
[9] Univ Leicester, Univ Hosp Leicester, Diabet Res Ctr, Leicester, Leics, England
来源：
DIABETOLOGIA | 2017年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
674
引用
收藏
页码：S307 / S307
页数：1
相关论文
共 50 条
  • [31] Real-World Effectiveness and Safety of Insulin Glargine 300 U/mL (gla-300) in Insulin-Naive Patients with Type 2 Diabetes (T2DM): Interim Analysis of the ATOS Study
    Galstyan, Gagik R.
    Bhansali, Anil
    Vargas-Uricoechea, Hernando
    Tirosh, Amir
    Sun, Guannan
    Naqvi, Mubarak
    Pilorget, Valerie
    Coudert, Mathieu
    Cherkasov, Dmitry
    Khan, Niaz
    DIABETES, 2020, 69
  • [32] Reported Pregnancy Outcomes with Insulin Glargine 100 U/mL (Gla-100) and 300 U/mL (Gla-300) : Post-Marketing Survey of Pharmacovigilance Data
    Westerbacka, Jukka
    Bassole, Caroline
    Duverne, Marielle
    Doder, Zoran
    Schoepper, Heike
    DIABETES, 2022, 71
  • [33] Glycaemic control in people with type 2 diabetes (T2D) switching from NPH to insulin glargine 300 U/mL (Gla-300): REALI pooled database
    Mueller-Wieland, D.
    Freemantle, N.
    Bonadonna, R.
    Mauquoi, C.
    Bigot, G.
    Bonnemaire, M.
    Gourdy, P.
    Mauricio, D.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S333 - S334
  • [34] Glycemic Control in People with Type 2 Diabetes (PWT2D) Switching from NPH to Insulin Glargine 300 U/mL (Gla-300) : REALI Pooled Database
    Mueller-Wieland, Dirk
    Freemantle, Nick
    Bonadonna, Riccardo C.
    Mauquoi, Celine
    Bigot, Gregory
    Bonnemaire, Mireille
    Gourdy, Pierre
    Mauricio, Didac
    DIABETES, 2022, 71
  • [35] OLDER PEOPLE WITH T2DM: GLYCEMIC CONTROL AND LESS HYPOGLYCEMIA WITH INSULIN GLARGINE 300 U/ML (GLA-300) VS GLA-100 AT 1 YEAR
    Yale, J. F.
    Trescoli, C.
    Cahn, A.
    Lee, M.
    Brulle-Wohlhueter, C.
    Chevalier, S.
    Bolli, G. B.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2016, 18 : A116 - A116
  • [36] Insulin Glargine 300 U/mL (Gla-300) vs 100 U/mL (Gla-100) in people > 75 years old with T2Dm: Secondary analysis of the SENIOR study
    Harris, Steward
    Vonbank, Alexander
    Ritzel, Robert
    Baron, Helen
    Florez, Hermes
    Espinasse, Melanie
    Muehlen-Bartmer, Iingrid
    Zangh, Nue
    Munshi, Medha
    WIENER KLINISCHE WOCHENSCHRIFT, 2018, 130 : 370 - 370
  • [37] Efficacy and Safety of Insulin Glargine 300 Units/mL (Gla-300) Versus Insulin Glargine 100 Units/mL (Gla-100) in Children and Adolescents (6-17 years) With Type 1 Diabetes: Results of the EDITION JUNIOR Randomized Controlled Trial
    Danne, Thomas
    Tamborlane, William V.
    Malievsky, Oleg A.
    Franco, Denise R.
    Kawamura, Tomoyuki
    Demissie, Marek
    Niemoeller, Elisabeth
    Goyeau, Harmonie
    Wardecki, Marek
    Battelino, Tadej
    DIABETES CARE, 2020, 43 (07) : 1512 - 1519
  • [38] DIFFERENCES BETWEEN INSULIN GLARGINE 300 U/ML (GLA-300) AND INSULIN DEGLUDEC 100 U/ML (IDEG) IN HIGH-RISK TYPE 2 DIABETES (T2DM) POPULATIONS: SUBANALYSIS OF THE BRIGHT TRIAL
    Cheng, A.
    Haluzik, M.
    Aroda, V.
    Roussel, R.
    Shehadeh, N.
    Bosnyak, Z.
    Lauand, F.
    Melas-Melt, L.
    Rosenstock, J.
    Bolli, G.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A89 - A89
  • [39] Reduced hypoglycemia and comparable efficacy with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in subjects with T2D achieving different levels of pre-breakfast SMPG
    Reid, Timothy
    Odugbesan, Ola
    Gill, Jasvinder
    Nikonov, Elena
    Chao, Jason
    Bailey, Timothy
    PHARMACOTHERAPY, 2016, 36 (12): : E231 - E231
  • [40] Effect of switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL (Gla-300) in Brazilian people with type 1 diabetes
    Dualib, Patricia Medici
    Dib, Sergio Atala
    Augusto, Gustavo Akerman
    Truzzi, Ana Cristina
    de Paula, Mauricio Aguiar
    Rea, Rosangela Roginski
    DIABETOLOGY & METABOLIC SYNDROME, 2024, 16 (01):
12345